During the last session, Werewolf Therapeutics Inc (NASDAQ:HOWL)’s traded shares were 0.36 million, with the beta value of the company hitting 0.31. At the end of the trading day, the stock’s price was $1.65, reflecting an intraday loss of -3.51% or -$0.06. The 52-week high for the HOWL share is $8.19, that puts it down -396.36 from that peak though still a striking 4.24% gain since the share price plummeted to a 52-week low of $1.58. The company’s market capitalization is $73.53M, and the average intraday trading volume over the past 10 days was 0.36 million shares, and the average trade volume was 730.23K shares over the past three months.

Werewolf Therapeutics Inc (HOWL) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. HOWL has a Sell rating from 0 analyst(s) out of 4 analysts who have looked at this stock. 1 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 3 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.31.

Werewolf Therapeutics Inc (NASDAQ:HOWL) trade information

Werewolf Therapeutics Inc (HOWL) registered a -3.51% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -3.51% in intraday trading to $1.65, hitting a weekly high. The stock’s 5-day price performance is -8.33%, and it has moved by -19.51% in 30 days. Based on these gigs, the overall price performance for the year is -41.07%. The short interest in Werewolf Therapeutics Inc (NASDAQ:HOWL) is 1.23 million shares and it means that shorts have 2.09 day(s) to cover.

The consensus price target of analysts on Wall Street is $12, which implies an increase of 86.25% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $12 and $12 respectively. As a result, HOWL is trading at a discount of -627.27% off the target high and -627.27% off the low.

Werewolf Therapeutics Inc (HOWL) estimates and forecasts

Statistics show that Werewolf Therapeutics Inc has underperformed its competitors in share price, compared to the industry in which it operates. Werewolf Therapeutics Inc (HOWL) shares have gone down -45.18% during the last six months, with a year-to-date growth rate less than the industry average at -48.57% against 17.10. In the rating firms’ projections, revenue will decrease -90.57% compared to the previous financial year.

As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 301.59k as predicted by 6 analyst(s). Meanwhile, a consensus of 4 analyst(s) estimates revenue growth to 375k by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 1.5M and 742k respectively. In this case, analysts expect current quarter sales to shrink by -79.91% and then drop by -49.46% in the coming quarter.

An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -13.31%. While earnings are projected to return -46.19% in 2024, the next five years will return 10.90% per annum.

HOWL Dividends

Werewolf Therapeutics Inc is due to release its next quarterly earnings in January. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.

The next largest institutional holding, with 4.28 million shares, is of MPM ASSET MANAGEMENT LLC’s that is approximately 10.2967% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $10.45 million.